The Ovarian Cancer Research Alliance provides information based on medical research and best practices. Research regarding a connection between the use of talcum powder and increased ovarian cancer risk is inconclusive. The verdict of a recent trial regarding talcum powder. will not change the information that the Ovarian Cancer Research Alliance provides to women about talcum … Continued
(February 22, 2016) Imagine a lighthouse on cancer cells that can tell the T-cells in our immune system precisely where to attack to stop cancer in its tracks. When working properly, that’s exactly what dendritic cells do. They break down cancer cells into antigens that T-cells can “read” and know to attack while sparing healthy … Continued
(January 27, 2016) A new study of 8,000 women reported in the Journal of the National Cancer Institute reports that carrying mutations in a gene called BRIP1 raised a woman’s chance of getting ovarian cancer in her lifetime to approximately 5%– nearly three times greater than chance women generally have of developing the cancer. Around … Continued
(Jan. 8, 2016) OCRF grantees Dr. Barbara Norquist and Dr. Elizabeth Swisher were part of a team that recently released a study which investigated the occurrence, and role of, inherited cancer associated genes in a randomly selected population of women diagnosed with ovarian cancer. The OCRF-supported study, published late last month in JAMA Oncology, found … Continued
(December 17, 2015) This morning in London, researchers announced the long-awaited final results of the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The trial showed that average-risk, post-menopausal women who were screened for ovarian cancer based on a test called ROCA (Risk of Ovarian Cancer Algorithm) were not less likely to die from … Continued
(12/14/15) | In 2015, OCRF grantees made several significant advances in the fight against ovarian cancer, including: These discoveries are the direct result of generous donations from people like you. Progress is made every day, and the future is full of promise – with even more important successes to come. Thank you for supporting cutting-edge … Continued
(December 4, 2015) According to the results of a phase III trial of over 1,000 women, women with advanced ovarian cancer gained significant delays in the progression of their disease when they were treated with the drug nintedanib plus carboplatin/paclitaxel, compared with women treated with carboplatin/paclitaxel alone. The results of the study were published in … Continued
(December 2, 2015) Research funded in part by an OCRF grant to Rachel Grisham, MD has identified new, potentially targetable mutations in patients with low grade serous ovarian cancer. Dr. Grisham is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York and is a 2014 recipient of the Liz Tilberis Early Career … Continued
(December 1, 2015) Research funded in part by Ovarian Cancer Research Fund, and published in PNAS, offers new insights into how ovarian cancer grows—and the potential to stop it. Can any cancer cell form another tumor, or is it only select cancer stem cells that give rise to new cancer cells? The answer, a new … Continued
(November 20, 2015) A study published in BMC Cancer demonstrates that ovarian cancer patients who had a history of oral contraceptive use had better outcomes than those who had not previously used them. Dr. Aminah Jatoi and co-author Dr. Ellen Goode, both of the Mayo Clinic, examined 1,398 cases during a thirteen year period and … Continued
(Nov. 19, 2016) In research published this month in Gynecologic Oncology, a group of Canadian researchers have found that long-term survival is not associated with BRCA mutation status in ovarian cancer patients. Past research has shown that after a diagnosis of ovarian cancer, positive BRCA mutation status confers a mortality benefit that diminishes with time. In … Continued
OCRF has awarded $5.2 million in new grants, bringing our total investment in ovarian cancer research to nearly $70 million.
Get email updates about research news, action alerts, and ways to join the fight.
